Patent ductus arteriosus (PDA) is a very common finding in extremely preterm infants less than 29 weeks of gestation. Persistent patency of the ductus arteriosus in preterm infants is unequivocally associated with increased morbidity and mortality. The prevailing opinion over the years was that closure of PDA would reduce the morbidity and mortality in extremely preterm infants. Numerous studies have outlined the use of medical and surgical treatment for ductal closure. While these studies have demonstrated effective closure of the ductus, the critical question remains whether medical or surgical closure of the PDA reduces morbidity and mortality.
| INTRODUC TI ON
Patent ductus arteriosus (PDA) is a very common finding in extremely preterm infants less than 29 weeks of gestation. Persistent patency of the ductus arteriosus in preterm infants is unequivocally associated with increased morbidity and mortality. The prevailing opinion over the years was that closure of PDA would reduce the morbidity and mortality in extremely preterm infants. Numerous studies have outlined the use of medical and surgical treatment for ductal closure. While these studies have demonstrated effective closure of the ductus, the critical question remains whether medical or surgical closure of the PDA reduces morbidity and mortality.
In this review, we will discuss the role of medical interventions to close the PDA in preterm infants. We will then address the association between treatments to close the PDA and outcomes and focus on the recent studies that explore the natural history of PDA in preterm infants.
| R ANDOMIZED TRIAL S OF TRE ATMENT TO ACHIE VE DUC TAL CLOSURE
Current medical treatments to promote PDA closure in preterm infants include use of prostaglandin synthase inhibitors, indomethacin and ibuprofen (cyclooxygenase inhibitors), and recently acetaminophen (peroxidase inhibitor), surgical ligation, and percutaneous placement of a vascular occluder. Although indomethacin and ibuprofen have been extensively studied in the preterm population and are effective in causing ductal closure, treatment is associated with significant renal and gastrointestinal side effects. Indomethacin causes a decrease in renal function by decreasing urine output and increase in serum creatinine levels. Indomethacin also decreases mesenteric perfusion and has been associated with spontaneous intestinal perforation with combined hydrocortisone use. 1 Ibuprofen causes fewer renal side effects compared to indomethacin, but has been shown to cause an increase in total and unbound serum bilirubin levels, the clinical significance of which is unknown. 2 There have been reports of pulmonary hypertension with ibuprofen prophylaxis for PDA in preterm infants. 3 Antenatal exposure to indomethacin for tocolysis may impact the ability of the ductus to close spontaneously after birth in preterm infants and require surgical ligation. 4 Recent studies have suggested that acetaminophen may be effective in closing the ductus in preterm infants, but the drug is not approved by FDA for that specific use. There is no clear evidence that one pharmacologic agent is superior to the other in the treatment of PDA in preterm infants. Based on the results of several randomized trials and meta-analyses, there is no evidence for short-or long-term benefits to close F I G U R E 1 Pooled results of randomized controlled trials of NSAID therapy for persistent patent ductus arteriosus in preterm infants. Bars represent 95% confidence limits and the line at the midpoint of each bar denotes the point estimate of the pooled odds ratio. Bars for odds ratio significantly different from 1 are red (2-tailed P < .05). The numbers of trials (N) and subjects (n) for each outcome are shown at the right (N/n). must be regarded as an untested and, therefore, unproven therapy.
The role of selective early treatment remains to be determined.
Thus, while there is evidence that medical interventions can close a ductus arteriosus, the question still remains, does intervention leading to closure of a ductus actually improve outcomes? in the early treatment group, oxygen requirements and mean airway pressures among infants <28 weeks and the overall incidence of major morbidities (including mortality) was higher in the early treatment group. (23 vs 8%; P = .017). 19 The hypothesis that treatment to close the PDA is supported by many widely shared anecdotes, but not by controlled experiments. It remains possible that such benefits may accrue to carefully selected candidates for treatment, however.
| S HORT-TERM EFFEC TS OF TRE ATMENT ON RE S PIR ATORY SUPP ORT

| E XPERIEN CE WITH NONINTERVENTI ONAL S TR ATEG IE S
Determining whether intervention to achieve closure of a ductus improves outcomes requires an understanding of the natural history of a PDA in the preterm neonate. Because of the widely held belief that treatment is beneficial, and therefore necessary, that natural history has been obscured by a lack of data on the trajectories of untreated preterm infants. Several recent studies, now including more than 1000 infants managed conservatively, have described the con- in the conservative management group. 26 Semberova et al recently illustrated spontaneous ductal closure in the majority of preterm neonates prior to discharge, with incidence of PDA inversely related to gestational age, in a cohort of infants managed with a conservative approach. While the duration of ductal patency increased with decreasing gestational age, with a median age at ductal closure of 71 days in patients <26 weeks of GA, they identified no significantly increased risk of morbidities such as BPD or NEC (Figure 2) . 27 These studies illustrate the concept that nonintervention does not appear to lead to increased morbidity or mortality.
Recent studies suggesting an association of increased morbidity and mortality with PDA ligation have caused concern among clinicians, likely contributing to an overall decrease in surgical ligations in extremely preterm infants. 29, 30 These concerns are offset by a recent study of 308 patients with a hemodynamically significant patent ductus arteriosus (HSPDA) after medication treatment failure, which compared those who were ligated (n = 166) to those who were not (n = 142). 31 Infants in the nonligated group achieved ductal closure at a median age of 42 days, compared to 28 days in the ligated group. Even among these infants who had failed medical treatment, the PDA closed spontaneously in more than 85% before discharge. There were no differences in neurodevelopmental outcomes at 18-24 months, chronic lung disease, or retinopathy of prematurity. However, nonligated patients had higher overall riskadjusted mortality rates; they were more likely to die during the first 28 postnatal days, and the difference appeared to be attributable to much higher rates of death from sepsis or major brain injury. The authors speculate that the observed difference in adjusted mortality may reflect confounding by contraindication, such that infant with sepsis or major brain injury may have been deemed too unstable to be candidates for surgical ligation. Accordingly, this experience implies that no advantage is gained from late surgical ligation, despite the substantially longer period of exposure to PDA in the nonligated group.
| E VIDEN CE FROM P OPUL ATION SURVE YS
A retrospective study of 13 853 VLBW infants in the Pediatric however. These authors noted that changes in practice, including the shift toward less PDA intervention, resulted in improvement in neonatal outcomes. 33 While the contribution of changing management of PDA to better outcomes is not certain, however, there is no clear evidence that nonintervention for a hemodynamically significant patent ductus leads to worse outcomes.
| CON CLUS IONS
Association does not equal causation; presence of a PDA does not mean that the PDA is the cause of necrotizing enterocolitis, BPD, or death, but may rather reflect guilt by association. There continues to be a lack of equipoise regarding ductal closure and benefits despite numerous studies, partly relating to significant treatment crossover among controls, due to inherent bias that a PDA leads to increased 
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